Hansoh Pharmaceutical Group (SEHK:3692) Valuation Check After Hang Seng China Enterprises Index Inclusion

Simply Wall St.06-11 01:18

AdvertisementHansoh Pharmaceutical Group added to Hang Seng China Enterprises Index Hansoh Pharmaceutical Group (SEHK:3692) has been added to the Hang Seng China Enterprises Index, a move that ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642752064?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-06-11 01:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642752064","market":"us","top_or_hot":-1,"title":"Hansoh Pharmaceutical Group (SEHK:3692) Valuation Check After Hang Seng China Enterprises Index Inclusion","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementHansoh Pharmaceutical Group added to Hang Seng China Enterprises Index Hansoh Pharmaceutical Group (SEHK:3692) has been added to the Hang Seng China Enterprises Index, a move that ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk3692-valuation-check-after-h\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharmaceutical Group (SEHK:3692) Valuation Check After Hang Seng China Enterprises Index Inclusion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharmaceutical Group (SEHK:3692) Valuation Check After Hang Seng China Enterprises Index Inclusion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-11 01:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk3692-valuation-check-after-h><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementHansoh Pharmaceutical Group added to Hang Seng China Enterprises Index Hansoh Pharmaceutical Group (SEHK:3692) has been added to the Hang Seng China Enterprises Index, a move that ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk3692-valuation-check-after-h\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk3692-valuation-check-after-h","article_id":"2642752064","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk3692-valuation-check-after-h","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2642752064","pubTimestamp":1781111934,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Hansoh Pharmaceutical Group added to Hang Seng China Enterprises Index\nHansoh Pharmaceutical Group (SEHK:3692) has been added to the Hang Seng China Enterprises Index, a move that increases the stock’s visibility and may influence flows from index-linked funds.\nSee our latest analysis for Hansoh Pharmaceutical Group.\nAlongside the index inclusion, Hansoh Pharmaceutical Group’s share price has been under pressure recently. It has a 30 day share price return of down 20.12% and a year to date...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1583":"高瓴概念","03692":"翰森制药","BK1191":"制药"},"translate_title":"翰森制药集团(SEHK：3692)纳入恒生国企指数后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1.98},"content_text":"AdvertisementHansoh Pharmaceutical Group added to Hang Seng China Enterprises Index Hansoh Pharmaceutical Group (SEHK:3692) has been added to the Hang Seng China Enterprises Index, a move that increases the stock’s visibility and may influence flows from index-linked funds. See our latest analysis for Hansoh Pharmaceutical Group. Alongside the index inclusion, Hansoh Pharmaceutical Group’s share price has been under pressure recently. It has a 30 day share price return of down 20.12% and a year to date share price return of down 19.59%, while its 3 year total shareholder return of 135.95% points to strong longer term gains. This suggests recent weakness contrasts with its broader track record. If this index move has you thinking about where else growth could come from in healthcare, it may be worth scanning 133 healthcare AI stocks. With the stock recently under pressure but showing a 3 year total shareholder return of 135.95%, and trading below some intrinsic and target value estimates, investors may be considering whether there is still an opportunity or whether potential future growth is already reflected in the price. Preferred P/E of 27.7x: Is it justified? Hansoh Pharmaceutical Group currently trades on a P/E of 27.7x, which sits against a last close of HK$29.30 and suggests the stock is priced well above many peers. The P/E multiple compares the current share price to earnings per share and is a quick way to see how much investors are paying for each unit of profit. For a profitable pharma company like Hansoh, it is often used as a shorthand for how the market views the durability and quality of its earnings. Here, the stock is described as expensive on several fronts. Its 27.7x P/E is higher than the Hong Kong Pharmaceuticals industry average of 13.2x and above the peer group average of 18.6x. It is also above an estimated fair P/E of 19x that our model suggests the market could move toward if pricing lined up more closely with underlying fundamentals. This gap between the current P/E and both industry and fair value markers is material. It signals that investors are currently paying a premium versus sector peers and the level the SWS fair ratio indicates could be more sustainable over the longer term. Explore the SWS fair ratio for Hansoh Pharmaceutical Group Result: Price-to-Earnings of 27.7x (OVERVALUED) However, that premium rating could be vulnerable if earnings growth slows, or if sector sentiment turns and more investors start favouring cheaper pharmaceutical stocks. Find out about the key risks to this Hansoh Pharmaceutical Group narrative. Another View: Cash Flows Point to Undervaluation While the P/E of 27.7x makes Hansoh Pharmaceutical Group look expensive, the SWS DCF model tells a different story. At a last close of HK$29.30, the stock trades about 47.3% below an estimated fair value of HK$55.59. This suggests the market may be pricing its future cash flows cautiously. Look into how the SWS DCF model arrives at its fair value. 3692 Discounted Cash Flow as at Jun 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hansoh Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 200 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps The mix of premium valuation signals and recent share price pressure can feel conflicting. It makes sense to move quickly and test the numbers yourself before opinions harden by reviewing the 4 key rewards and 1 important warning sign. Looking for more investment ideas? If this update has sharpened your thinking on Hansoh, take the next step and line up a few alternative ideas that could strengthen your overall portfolio.  Target potential upside by scanning companies that screen as 200 high quality undervalued stocks, and see which stocks currently trade below their assessed worth. Prioritise resilience by checking out 274 resilient stocks with low risk scores, focusing on stocks with characteristics that may help reduce portfolio volatility. Hunt for fresh opportunities away from crowded trades by reviewing the screener containing 507 high quality undiscovered gems, where smaller, less followed stocks still meet solid fundamentals criteria.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Hansoh Pharmaceutical Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642752064","isCrawlerRequest":true}